(Alliance News) - Blue-chip benchmarks in London and Paris hit record highs on Thursday, with the FTSE 100 managing to cling to its daily gain, despite some weakness following US producer price data. Read More
(Alliance News) - Stock prices in London were higher at midday on Thursday, with London's flagship index still trading above the 8,000 mark on the back of strong performances from Centrica and Relx. Read More
(Alliance News) - Indivior PLC on Thursday reported a swing to a full-year loss due to a provision for litigation, despite net revenue jumping by 14% due to growth in its Sublocade injection. Read More
(Alliance News) - Stock prices in London opened higher on Thursday, with London's blue-chip index pushing past the 8,000 mark once again, a day after it first broke the barrier. Read More
(Alliance News) - Stocks in London were set to open higher on Thursday, with the FTSE 100 called to push past the 8,000 mark again at the open. Read More
(Alliance News) - Indivior PLC has announced on Monday the expiration of the waiting period relating to its USD145 million purchase of Opiant Pharmaceuticals Inc. Read More
(Alliance News) - Stocks in London closed in the red on Wednesday, despite a strong performance from pharmaceutical stocks, as investors digested a raft of economic data from both China and Europe. Read More
(Alliance News) - Indivior PLC on Wednesday said it aims to list on the Nasdaq in spring 2023 as it expects its injection Sublocade to reach peak annual net revenue of over USD1.5 billion. Read More
(Alliance News) - Indivior PLC on Thursday reported a double-digit rise in both quarterly net revenue and profit, as it raises its full-year guidance. Read More
(Alliance News): Indivior PLC on Thursday reported a "strong" performance in the first half of 2022, even as profit fell due to by investments in opioid mediation Sublocade. Read More
